Novartis AG
METHOD OF TREATING TENDINOPATHY USING INTERLEUKIN-17 (IL-17)

Last updated:

Abstract:

The present disclosure relates to methods for treating tendinopathy, e.g., rotator cuff tendinopathy, using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating tendinopathy patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Status:
Application
Type:

Utility

Filling date:

1 Nov 2018

Issue date:

17 Jun 2021